PBHNYSEPharmaceutical PreparationsFiscal year ends March 31

Prestige Consumer Healthcare Inc.

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$49.71−0.21 (-0.42%)

Close on Oct 19, 2026

Market cap: $2.37B
P/E (TTM): 13.9
Dividend yield: –

Prestige Consumer Healthcare Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31	FY 2020 2020-03-31	FY 2019 2019-03-31	FY 2018 2018-03-31	FY 2017 2017-03-31	FY 2016 2016-03-31	FY 2015 2015-03-31	FY 2014 2014-03-31	FY 2013 2013-03-31	FY 2012 2012-03-31	FY 2011 2011-03-31	FY 2010 2010-03-31
Revenue	1,089	1,138	1,125	1,128	1,087	943	963	976	1,041	882	806	715	597	617	441	337	293
Cost of Revenue	493	503	501	502	466	396	411	420	465	382	339	–	–	–	–	–	–
Gross Profit	596	634	624	625	621	547	552	556	577	500	467	406	336	344	227	171	153
General & Administrative	116	108	106	107	107	83	89	90	85	89	72	81	48	51	57	42	34
Advertising Expenses	149	156	153	145	157	141	147	143	147	128	111	100	85	87	57	43	31
Operating Expenses	286	298	282	648	291	250	261	488	361	295	207	199	147	152	125	95	75
Operating Income	309	337	342	-22	330	297	291	68	215	206	260	208	189	192	103	76	78
Interest Expense	–	1.80	5.20	4.40	64	82	96	105	106	94	85	81	69	84	41	27	23
Interest & Investment Income	–	–	–	–	–	–	0.34	0.22	0.39	0.20	0.16	0.09	0.06	0.01	0.02	0.00	0.00
Other Non-Operating Income	-9.57	-4.95	0.76	-2.34	-1.05	1.37	-1.63	-0.48	0.39	-0.03	–	–	–	–	–	–	–
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	2.75
Asset Impairment Charges	0	12	0	370	1.06	2.43	0	229	100	0	0	0	0	–	–	–	–
Gain (Loss) on Sale of Assets	-0.17	-0.23	-0.27	-0.27	-0.27	-0.22	-0.71	-0.22	-1.57	-0.57	0.04	-0.32	0.00	0	0	-0.15	0
Legal Settlements	–	–	–	–	–	–	–	–	–	–	–	–	0	0	5.06	0	0
Pretax Income	257	284	276	-94	262	204	191	-38	107	111	157	127	102	106	61	49	53
Income Tax Expense	67	70	67	-12	57	39	49	-2.26	-232	41	57	49	29	41	24	19	21
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	78	73	66	37	29	32
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0.04	-0.11
Net Income	190	215	209	-82	205	165	142	-36	340	69	100	78	73	66	37	29	32
EPS (Basic)(per share)	3.93	4.32	4.21	-1.65	4.09	3.28	2.81	-0.69	6.40	1.31	1.89	1.50	1.41	1.29	0.74	0.58	0.64
EPS (Diluted)(per share)	3.91	4.29	4.17	-1.65	4.04	3.25	2.78	-0.69	6.34	1.30	1.88	1.49	1.39	1.27	0.73	0.58	0.64
Shares Outstanding (Basic, Weighted)(shares)	48	50	50	50	50	50	51	52	53	53	53	52	52	51	50	50	50
Shares Outstanding (Diluted, Weighted)(shares)	49	50	50	50	51	51	51	52	54	53	53	53	52	51	51	50	50
EBITDA	341	367	373	10	362	328	320	99	249	231	284	225	202	205	114	86	90
Net Interest Income	-42	-48	-67	-69	-64	–	–	–	–	–	–	–	–	–	–	–	–
Provision for Credit Losses	10	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 53.5%
Operating margin: 26.3%
Net margin: 15.6%
Return on equity, FY2026: 10.2%

Financial strength

Current ratio: 3.23
Debt to equity: 1.05
Debt to assets: 44.2%
Cash to current liabilities: 57.9%

Valuation

P/E ratio: 13.9
Price to sales: 2.14
Price to book: 1.23
Dividend yield: –